BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Cai L, Cai X. Up-regulation of miR-9 expression predicate advanced clinicopathological features and poor prognosis in patients with hepatocellular carcinoma. Diagn Pathol. 2014;9:1000. [PMID: 25552204 DOI: 10.1186/s13000-014-0228-2] [Cited by in Crossref: 32] [Cited by in F6Publishing: 37] [Article Influence: 4.6] [Reference Citation Analysis]
Number Citing Articles
1 Li S, Li T, Li X, Yao Y, Jiang X, Zhao L, Guo W. MicroRNA-32 Regulates Development and Progression of Hepatocellular Carcinoma by Targeting ADAMTS9 and Affects Its Prognosis. Med Sci Monit Basic Res 2018;24:177-87. [PMID: 30393368 DOI: 10.12659/MSMBR.910522] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 1.7] [Reference Citation Analysis]
2 Ferreira HJ, Esteller M. Non-coding RNAs, epigenetics, and cancer: tying it all together. Cancer Metastasis Rev 2018;37:55-73. [PMID: 29374363 DOI: 10.1007/s10555-017-9715-8] [Cited by in Crossref: 47] [Cited by in F6Publishing: 37] [Article Influence: 23.5] [Reference Citation Analysis]
3 Kanda M, Sugimoto H, Kodera Y. Genetic and epigenetic aspects of initiation and progression of hepatocellular carcinoma. World J Gastroenterol. 2015;21:10584-10597. [PMID: 26457018 DOI: 10.3748/wjg.v21.i37.10584] [Cited by in CrossRef: 37] [Cited by in F6Publishing: 41] [Article Influence: 7.4] [Reference Citation Analysis]
4 Bronte F, Bronte G, Fanale D, Caruso S, Bronte E, Bavetta MG, Fiorentino E, Rolfo C, Bazan V, Di Marco V, Russo A. HepatomiRNoma: The proposal of a new network of targets for diagnosis, prognosis and therapy in hepatocellular carcinoma. Crit Rev Oncol Hematol 2016;97:312-21. [PMID: 26603462 DOI: 10.1016/j.critrevonc.2015.09.007] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 3.5] [Reference Citation Analysis]
5 Yu J, Yang M, Zhou B, Luo J, Zhang Z, Zhang W, Yan Z. CircRNA-104718 acts as competing endogenous RNA and promotes hepatocellular carcinoma progression through microRNA-218-5p/TXNDC5 signaling pathway. Clinical Science 2019;133:1487-503. [DOI: 10.1042/cs20190394] [Cited by in Crossref: 44] [Cited by in F6Publishing: 30] [Article Influence: 22.0] [Reference Citation Analysis]
6 Wang T, Ma S, Qi X, Tang X, Cui D, Wang Z, Chi J, Li P, Zhai B. Long noncoding RNA ZNFX1-AS1 suppresses growth of hepatocellular carcinoma cells by regulating the methylation of miR-9. Onco Targets Ther 2016;9:5005-14. [PMID: 27574442 DOI: 10.2147/OTT.S103329] [Cited by in Crossref: 15] [Cited by in F6Publishing: 11] [Article Influence: 3.0] [Reference Citation Analysis]
7 Chen ZH, Hong YF, Lin J, Li X, Wu DH, Wen JY, Chen J, Ruan DY, Lin Q, Dong M, Wei L, Wang TT, Lin ZX, Ma XK, Wu XY, Xu R. Validation and ranking of seven staging systems of hepatocellular carcinoma. Oncol Lett 2017;14:705-14. [PMID: 28693224 DOI: 10.3892/ol.2017.6222] [Cited by in Crossref: 8] [Cited by in F6Publishing: 11] [Article Influence: 2.0] [Reference Citation Analysis]
8 Chen L, Zhou H, Guan Z. CircRNA_000543 knockdown sensitizes nasopharyngeal carcinoma to irradiation by targeting miR-9/platelet-derived growth factor receptor B axis. Biochemical and Biophysical Research Communications 2019;512:786-92. [DOI: 10.1016/j.bbrc.2019.03.126] [Cited by in Crossref: 27] [Cited by in F6Publishing: 26] [Article Influence: 13.5] [Reference Citation Analysis]
9 Leonardi L, Scotlandi K, Pettinari I, Benassi MS, Porcellato I, Pazzaglia L. MiRNAs in Canine and Human Osteosarcoma: A Highlight Review on Comparative Biomolecular Aspects. Cells 2021;10:428. [PMID: 33670554 DOI: 10.3390/cells10020428] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
10 Drakaki A, Hatziapostolou M, Polytarchou C, Vorvis C, Poultsides GA, Souglakos J, Georgoulias V, Iliopoulos D. Functional microRNA high throughput screening reveals miR-9 as a central regulator of liver oncogenesis by affecting the PPARA-CDH1 pathway. BMC Cancer 2015;15:542. [PMID: 26206264 DOI: 10.1186/s12885-015-1562-9] [Cited by in Crossref: 44] [Cited by in F6Publishing: 43] [Article Influence: 7.3] [Reference Citation Analysis]
11 Wang YW, Chen X, Ma R, Gao P. Understanding the CREB1-miRNA feedback loop in human malignancies. Tumour Biol 2016;37:8487-502. [PMID: 27059735 DOI: 10.1007/s13277-016-5050-x] [Cited by in Crossref: 17] [Cited by in F6Publishing: 20] [Article Influence: 3.4] [Reference Citation Analysis]
12 Ito T, Igaki T. Yorkie drives Ras-induced tumor progression by microRNA-mediated inhibition of cellular senescence. Sci Signal 2021;14:eaaz3578. [PMID: 34074704 DOI: 10.1126/scisignal.aaz3578] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
13 Xiao D, Gao HX. Mechanism of miR-107-targeting of regulator of G-protein signaling 4 in hepatocellular carcinoma. Oncol Lett 2019;18:5145-54. [PMID: 31612026 DOI: 10.3892/ol.2019.10857] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
14 Barbano R, Pasculli B, Rendina M, Fontana A, Fusilli C, Copetti M, Castellana S, Valori VM, Morritti M, Graziano P, Luigi C, Coco M, Picardo F, Mazza T, Evron E, Murgo R, Maiello E, Esteller M, Fazio VM, Parrella P. Stepwise analysis of MIR9 loci identifies miR-9-5p to be involved in Oestrogen regulated pathways in breast cancer patients. Sci Rep 2017;7:45283. [PMID: 28345661 DOI: 10.1038/srep45283] [Cited by in Crossref: 26] [Cited by in F6Publishing: 23] [Article Influence: 6.5] [Reference Citation Analysis]
15 Ralla B, Busch J, Flörcken A, Westermann J, Zhao Z, Kilic E, Weickmann S, Jung M, Fendler A, Jung K. miR-9-5p in Nephrectomy Specimens is a Potential Predictor of Primary Resistance to First-Line Treatment with Tyrosine Kinase Inhibitors in Patients with Metastatic Renal Cell Carcinoma. Cancers (Basel) 2018;10:E321. [PMID: 30201928 DOI: 10.3390/cancers10090321] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
16 Kim H, Kim T, Jaygal G, Woo J, Kim CJ, Baek MJ, Jeong D. Downregulation of miR-9 correlates with poor prognosis in colorectal cancer. Pathol Res Pract 2020;216:153044. [PMID: 32703504 DOI: 10.1016/j.prp.2020.153044] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
17 Fu Q, Yang F, Xiang T, Huai G, Yang X, Wei L, Yang H, Deng S. A novel microRNA signature predicts survival in liver hepatocellular carcinoma after hepatectomy. Sci Rep 2018;8:7933. [PMID: 29785036 DOI: 10.1038/s41598-018-26374-9] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 3.3] [Reference Citation Analysis]
18 Naidu S, Magee P, Garofalo M. MiRNA-based therapeutic intervention of cancer. J Hematol Oncol 2015;8:68. [PMID: 26062952 DOI: 10.1186/s13045-015-0162-0] [Cited by in Crossref: 73] [Cited by in F6Publishing: 64] [Article Influence: 12.2] [Reference Citation Analysis]
19 Wang H, Zhang W, Zuo Y, Ding M, Ke C, Yan R, Zhan H, Liu J, Wang J. miR-9 promotes cell proliferation and inhibits apoptosis by targeting LASS2 in bladder cancer. Tumour Biol 2015;36:9631-40. [PMID: 26150338 DOI: 10.1007/s13277-015-3713-7] [Cited by in Crossref: 38] [Cited by in F6Publishing: 36] [Article Influence: 6.3] [Reference Citation Analysis]
20 Bao Y, Zhang Y, Lu Y, Guo H, Dong Z, Chen Q, Zhang X, Shen W, Chen W, Wang X. Overexpression of microRNA-9 enhances cisplatin sensitivity in hepatocellular carcinoma by regulating EIF5A2-mediated epithelial-mesenchymal transition. Int J Biol Sci 2020;16:827-37. [PMID: 32071552 DOI: 10.7150/ijbs.32460] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 6.0] [Reference Citation Analysis]
21 Sun H, Shao Y, Huang J, Sun S, Liu Y, Zhou P, Yang H. Prognostic value of microRNA-9 in cancers: a systematic review and meta-analysis. Oncotarget 2016;7:67020-32. [PMID: 27563807 DOI: 10.18632/oncotarget.11466] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
22 Liu X, Luo Z, Peng H, Jiang H, Xu L. Prognostic role of miR-9 expression in various human malignant neoplasms: a meta-analysis. Onco Targets Ther 2016;9:3039-47. [PMID: 27284255 DOI: 10.2147/OTT.S98923] [Cited by in Crossref: 2] [Cited by in F6Publishing: 6] [Article Influence: 0.4] [Reference Citation Analysis]
23 Zhang Y, Wei C, Guo CC, Bi RX, Xie J, Guan DH, Yang CH, Jiang YH. Prognostic value of microRNAs in hepatocellular carcinoma: a meta-analysis. Oncotarget 2017;8:107237-57. [PMID: 29291025 DOI: 10.18632/oncotarget.20883] [Cited by in Crossref: 13] [Cited by in F6Publishing: 15] [Article Influence: 3.3] [Reference Citation Analysis]
24 Hang C, Yan HS, Gong C, Gao H, Mao QH, Zhu JX. MicroRNA-9 inhibits gastric cancer cell proliferation and migration by targeting neuropilin-1. Exp Ther Med 2019;18:2524-30. [PMID: 31572503 DOI: 10.3892/etm.2019.7841] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
25 Khafaei M, Rezaie E, Mohammadi A, Shahnazi Gerdehsang P, Ghavidel S, Kadkhoda S, Zorrieh Zahra A, Forouzanfar N, Arabameri H, Tavallaie M. miR-9: From function to therapeutic potential in cancer. J Cell Physiol 2019. [PMID: 30693512 DOI: 10.1002/jcp.28210] [Cited by in Crossref: 16] [Cited by in F6Publishing: 11] [Article Influence: 8.0] [Reference Citation Analysis]
26 Qiu LP, Wu YH, Yu XF, Tang Q, Chen L, Chen KP. The Emerging Role of Circular RNAs in Hepatocellular Carcinoma. J Cancer. 2018;9:1548-1559. [PMID: 29760792 DOI: 10.7150/jca.24566] [Cited by in Crossref: 39] [Cited by in F6Publishing: 45] [Article Influence: 13.0] [Reference Citation Analysis]
27 Tang S, Wu WK, Li X, Wong SH, Wong N, Chan MT, Sung JJ, Yu J. Stratification of Digestive Cancers with Different Pathological Features and Survival Outcomes by MicroRNA Expression. Sci Rep 2016;6:24466. [PMID: 27080237 DOI: 10.1038/srep24466] [Cited by in Crossref: 25] [Cited by in F6Publishing: 21] [Article Influence: 5.0] [Reference Citation Analysis]
28 Yu S, Liu X, Zhang Y, Li J, Chen S, Zheng H, Reng R, Zhang C, Chen J, Chen L. Circulating microRNA124-3p, microRNA9-3p and microRNA196b-5p may be potential signatures for differential diagnosis of thyroid nodules. Oncotarget 2016;7:84165-77. [PMID: 27705935 DOI: 10.18632/oncotarget.12389] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 5.0] [Reference Citation Analysis]
29 Song T, Liang Y, Cao Z, Du W, Li Y. Computational Analysis of Specific MicroRNA Biomarkers for Noninvasive Early Cancer Detection. Biomed Res Int 2017;2017:4680650. [PMID: 28357401 DOI: 10.1155/2017/4680650] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
30 Tran DDH, Kessler C, Niehus SE, Mahnkopf M, Koch A, Tamura T. Myc target gene, long intergenic noncoding RNA, Linc00176 in hepatocellular carcinoma regulates cell cycle and cell survival by titrating tumor suppressor microRNAs. Oncogene 2018;37:75-85. [DOI: 10.1038/onc.2017.312] [Cited by in Crossref: 46] [Cited by in F6Publishing: 41] [Article Influence: 11.5] [Reference Citation Analysis]
31 Mohammadi-yeganeh S, Mansouri A, Paryan M. Targeting Of miR9/NOTCH1 Interaction Reduces Metastatic Behavior in Triple-negative Breast Cancer. Chem Biol Drug Des 2015;86:1185-91. [DOI: 10.1111/cbdd.12584] [Cited by in Crossref: 33] [Cited by in F6Publishing: 28] [Article Influence: 5.5] [Reference Citation Analysis]
32 Shi C, Xu X. MiR-670-5p induces cell proliferation in hepatocellular carcinoma by targeting PROX1. Biomed Pharmacother 2016;77:20-6. [PMID: 26796260 DOI: 10.1016/j.biopha.2015.07.030] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.5] [Reference Citation Analysis]
33 Ding G, Peng Z, Shang J, Kang Y, Ning H, Mao C. LincRNA-p21 inhibits invasion and metastasis of hepatocellular carcinoma through miR-9/E-cadherin cascade signaling pathway molecular mechanism. Onco Targets Ther. 2017;10:3241-3247. [PMID: 28721075 DOI: 10.2147/ott.s134910] [Cited by in Crossref: 18] [Cited by in F6Publishing: 13] [Article Influence: 4.5] [Reference Citation Analysis]
34 Zheng H, Zou AE, Saad MA, Wang XQ, Kwok JG, Korrapati A, Li P, Kisseleva T, Wang-Rodriguez J, Ongkeko WM. Alcohol-dysregulated microRNAs in hepatitis B virus-related hepatocellular carcinoma. PLoS One. 2017;12:e0178547. [PMID: 28562643 DOI: 10.1371/journal.pone.0178547] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 2.3] [Reference Citation Analysis]
35 Cătană CS, Pichler M, Giannelli G, Mader RM, Berindan-Neagoe I. Non-coding RNAs, the Trojan horse in two-way communication between tumor and stroma in colorectal and hepatocellular carcinoma. Oncotarget 2017;8:29519-34. [PMID: 28392501 DOI: 10.18632/oncotarget.15706] [Cited by in Crossref: 15] [Cited by in F6Publishing: 17] [Article Influence: 5.0] [Reference Citation Analysis]
36 Shen S, Lin Y, Yuan X, Shen L, Chen J, Chen L, Qin L, Shen B. Biomarker MicroRNAs for Diagnosis, Prognosis and Treatment of Hepatocellular Carcinoma: A Functional Survey and Comparison. Sci Rep. 2016;6:38311. [PMID: 27917899 DOI: 10.1038/srep38311] [Cited by in Crossref: 44] [Cited by in F6Publishing: 44] [Article Influence: 8.8] [Reference Citation Analysis]
37 Wu Y, Tang Y, Xie S, Zheng X, Zhang S, Mao J, Wang B, Hou Y, Hu L, Chai K, Chen W. Chimeric peptide supramolecular nanoparticles for plectin-1 targeted miRNA-9 delivery in pancreatic cancer. Theranostics 2020;10:1151-65. [PMID: 31938057 DOI: 10.7150/thno.38327] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 10.0] [Reference Citation Analysis]